Genomed Spólka Akcyjna (WSE: GEN)

Market Cap	37.26M
Revenue (ttm)	23.06M
Net Income (ttm)	877.20K
Shares Out	1.32M
EPS (ttm)	0.66
PE Ratio	42.48
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	71
Open	28.80
Previous Close	29.00
Day's Range	28.80 - 28.80
52-Week Range	25.20 - 33.40
Beta	-0.03
RSI	60.44
Earnings Date	Feb 14, 2025

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 6,500 genes; and next-generation sequencing technology. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis, and the sequencing of phage genetic material, ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 44
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GEN

Financial Performance

In 2023, Genomed Spólka Akcyjna's revenue was 22.48 million, an increase of 9.88% compared to the previous year's 20.46 million. Earnings were 926,248, an increase of 174.07%.